retatrutide fda approval status 2025 HAS NOT BEEN APPROVED YET & CURRENTLY IN PHASE III CLINICAL TRIALS⛔️ Retatrutide is not currently FDA-approved, as it is in Phase III clinical trials with anticipated completion in 2025–2026 and Semaglutide vs. Retatrutide: A Comparison
Description
In research pertaining to psoriasis, one case report does exist showing exacerbation of lesions after initiation of liraglutide in addition to a placebo-controlled, randomized study that showed no change in severity of psoriasis in glucose tolerant patients between the group treated with a GLP-1RAs and the control
Important context: the FDA has warned that retatrutide is not a component of an FDA-approved drug and has not been found safe/effective for any condition
Common gastrointestinal side effects include nausea, constipation, diarrhoea and abdominal discomfort, typically mild and transient
Dosing protocols and clinical evidence
You may not realize just how much your lifestyle has changed after stopping semaglutide
Step 6: No Refunds, No Support Attempts to contact the vendor usually fail
